|1.||Yamanaka, Hisashi: 4 articles (10/2013 - 01/2005)|
|2.||Horwitz, Lawrence D: 4 articles (09/2008 - 06/2002)|
|3.||Sagawa, Akira: 3 articles (01/2016 - 01/2006)|
|4.||Tsuji, Fumio: 3 articles (09/2012 - 09/2009)|
|5.||Aono, Hiroyuki: 3 articles (09/2012 - 09/2009)|
|6.||Yoshino, S: 3 articles (05/2006 - 11/2000)|
|7.||Nagashima, M: 3 articles (05/2006 - 11/2000)|
|8.||Matsubara, Tsukasa: 2 articles (01/2016 - 01/2005)|
|9.||Suda, Akiko: 2 articles (01/2014 - 01/2008)|
|10.||Nagaoka, Shouhei: 2 articles (01/2014 - 01/2008)|
06/01/1993 - "Bucillamine: N-(2-mercapto-2-methyl-propanoyl)-L-cysteine has recently been suggested to be effective in the treatment of rheumatoid arthritis (RA). "
06/01/2011 - "A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)."
01/01/1993 - "Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis."
01/01/2015 - "She was receiving bucillamine as initial treatment for recently diagnosed rheumatoid arthritis, and renal biopsy showed MN with crescent formation. "
01/01/2015 - "Bucillamine is used for the treatment of rheumatoid arthritis. "
07/01/2010 - "Also bucillamine, that is a pseudo dipeptide possessing a thiol group capable to form an internal disulfide bridge, has relevant scavenger properties used in therapy for the treatment of arthritis. "
02/01/1999 - "In July 1993, bucillamine (BU) was started at a dose of 100 mg/day, and her arthritis subsided. "
09/01/1992 - "Five months previously, he had noted polyarthritis, and treatment with bucillamine was started in May 1990. "
01/01/1993 - "Long-term administration of bucillamine markedly improved arthritis and suppressed the titre of rheumatoid arthritis haemagglutination. "
05/01/1991 - "The effects of bucillamine, a new antirheumatic drug, on type II collagen induced arthritis in rats was examined. "
|3.||Nephrotic Syndrome (Syndrome, Nephrotic)
11/01/1992 - "Discontinuation of bucillamine led to complete remission of the nephrotic syndrome within 1 year. "
01/01/1991 - "After discontinuance of bucillamine, the nephrotic syndrome improved slowly with or without corticosteroid therapy. "
11/01/1992 - "They had received 200 mg bucillamine orally per day for 3-4 months before the onset of the nephrotic syndrome. "
06/01/1991 - "The nephrotic syndrome occurred after six months' and five months' treatment of bucillamine, respectively. "
01/01/1991 - "Results confirmed that the most common lesion of nephrotic syndrome associated with bucillamine therapy in RA is MGN. "
04/01/2002 - "After bucillamine was withdrawn, the fever and the abnormal chest shadows improved. "
09/01/1992 - "After stopping bucillamine, the fever, dry cough, and DOE improved gradually, and the abnormal shadows on chest X-ray and ABG analysis showed moderate improvements. "
09/01/1992 - "His polyarthritis improved about 2.5 months after starting bucillamine, but he developed fever, dry cough, and DOE in August 1990. "
01/01/2003 - "In an investigator-blinded, rigorous intact dog model, consisting of 90 min of coronary artery occlusion and 48 h of reperfusion, bucillamine, given i.v. during the first 3 h of reperfusion, substantially reduced myocardial infarct size. "
01/01/2003 - "On the basis of pharmacokinetic analyses of blood levels during these studies it was concluded that bucillamine, infused at i.v. doses > or =10 mg/kg/h for 3 h to humans could be expected to be therapeutically effective in myocardial infarction, organ transplantation and other acute inflammatory syndromes."
01/01/2003 - "Bucillamine has potential to attenuate or prevent damage during myocardial infarction, cardiac surgery and organ transplantation. "
09/01/2008 - "We tested the ability of a potent dithiol antioxidant, bucillamine, to protect against the long-term consequences of I/R injury in a murine model of myocardial infarction. "
|6.||Immunoglobulin G (IgG)
|7.||Antirheumatic Agents (DMARD)
|9.||Gold Sodium Thiomalate (Sodium Aurothiomalate)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)